Leveraging Amyris' industry-leading biotechnology platform in Beauty for
the development and supply of clean sustainable ingredients
EMERYVILLE, Calif., April 5,
2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a
leading synthetic biotechnology company accelerating the world's
transition to sustainable consumption through its Lab-to-Market™
technology platform and clean beauty consumer brands, announced
that it has completed the previously announced strategic
transaction with Givaudan SA for the worldwide exclusive licensing
of certain cosmetic ingredients, including Neossance® Squalane, the
highest performant emollient, Neossance® Hemisqualane, the
plant-based silicone alternative, and CleanScreen™, the sustainable
sun protector.
Givaudan is a global leader in Fragrance & Beauty. Amyris
and Givaudan have a strong partnership to leverage the value of
Amyris' technology platform for designing, scaling and
manufacturing the best-performing bio-fermented ingredients. This
marketing partnership builds on a successful history that includes
the development and commercialization of the world's leading supply
of Bisabolol from Amyris' precision fermentation platform.
"We are very pleased with the expansion of our long-term
partnership with Givaudan," said John
Melo, President and Chief Executive Officer. "This
transaction marks the continuation of the successful execution of
our strategy to develop, scale and make the world's best-performing
molecules from clean, sustainable chemistry and to partner with the
world's leading companies. We own the technology, and we formulate
and deliver the best-performing consumer products through our
portfolio of best-in-category consumer brands, which drives market
demand and adoption of our ingredients. Our ingredients partners
use their market reach to ensure a steady, reliable supply to
leading beauty and personal care companies."
The terms of the deal include a combination of a $200 million upfront cash consideration and up to
a $150 million performance based
earnout, along with a long-term manufacturing agreement that values
the total transaction at an estimated $500
million.
About Amyris
Amyris (Nasdaq: AMRS) is a leading
synthetic biotechnology company,
transitioning the Clean Health & Beauty and Flavors
& Fragrances markets to sustainable ingredients through
fermentation and the company's proprietary
Lab-to-Market™ technology platform. This Amyris platform
leverages state- of-the-art machine learning, robotics and
artificial intelligence, enabling the company to rapidly bring new
innovation to market at commercial scale. Amyris ingredients are
included in over 20,000 products from the world's top brands,
reaching more than 300 million consumers. Amyris also owns
and operates a family of consumer brands that is
constantly evolving to meet the
growing demand for sustainable, effective and accessible
products. For more information, please visit
http://www.amyris.com.
About Givaudan
Givaudan is a global leader in
Fragrance & Beauty and Taste & Wellbeing. We celebrate the
beauty of human experience by creating for happier, healthier lives
with love for nature. Together with our
customers we deliver food experiences, craft inspired fragrances and develop beauty
and wellbeing solutions that make people look and feel good.
In 2022, Givaudan employed almost 16,700 people worldwide and
achieved CHF 7.1 billion in sales
with a free cash flow of 6.7% of sales. With a heritage that
stretches back over 250 years, we are committed to driving
long-term, purpose-led growth by improving people's health and
happiness and increasing our positive impact on nature.
This is Givaudan. Human by nature.
Discover more at www.givaudan.com.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among other
things, statements regarding future events, such as Amyris'
strategy and expectations regarding the benefits and total value of
the strategic transaction with Givaudan. These statements are based
on management's current expectations and actual results and future
events may differ materially due to risks and uncertainties,
including risks related to Amyris' liquidity and ability to fund
operating and capital expenses, risks related to its financing
activities, risks related to potential delays or failures in
completing and integrating planned acquisitions, risks related to
potential delays or failures in development, regulatory approval,
launch, production and commercialization of products, risks related
to global inflation and policy measures undertaken to address
inflation, the COVID-19 pandemic and any other geopolitical events,
including the Ukraine conflict,
resulting in global economic, financial and supply chain
disruptions that may negatively impact Amyris' business operations
and financial results or cause market volatility, risks related to
Amyris' reliance on third parties particularly in the supply chain,
and other risks detailed from time to time in filings Amyris makes
with the Securities and Exchange Commission, including Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. Amyris disclaims any obligation to update
information contained in these forward-looking statements, whether
as a result of new information, future events, or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-closes-strategic-transaction-with-givaudan-301790447.html
SOURCE Amyris, Inc.